Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer-Reference-Cited by-同舟云学术

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

Published:2024-03-23 Issue:4 Volume:46 Page:2827-2844
ISSN:1467-3045
Container-title:Current Issues in Molecular Biology
language:en
Short-container-title:CIMB

Author:

Stefanoudakis Dimitrios¹^ORCID,Frountzas Maximos¹^ORCID,Schizas Dimitrios²^ORCID,Michalopoulos Nikolaos V.¹,Drakaki Alexandra³^ORCID,Toutouzas Konstantinos G.¹

Affiliation:

1. First Propaedeutic Department of Surgery, Hippocration General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece

2. First Department of Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece

3. Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA

Abstract

The present review demonstrates the major tumor suppressor genes, including TP53, CDKN2A and SMAD4, associated with pancreatic cancer. Each gene’s role, prevalence and impact on tumor development and progression are analyzed, focusing on the intricate molecular landscape of pancreatic cancer. In addition, this review underscores the prognostic significance of specific mutations, such as loss of TP53, and explores some potential targeted therapies tailored to these molecular signatures. The findings highlight the importance of genomic analyses for risk assessment, early detection and the design of personalized treatment approaches in pancreatic cancer. Overall, this review provides a comprehensive analysis of the molecular intricacies of pancreatic tumors, paving the way for more effective and tailored therapeutic interventions.

Publisher

MDPI AG

Link

https://www.mdpi.com/1467-3045/46/4/177/pdf

Reference125 articles.

1. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023

2. (2023, December 02). Pathology Outlines. Available online: https://www.pathologyoutlines.com/topic/pancreaswho.html.

3. Pancreatic cancer;Maitra;Annu. Rev. Pathol.,2008

4. Saiki, Y., Jiang, C., Ohmuraya, M., and Furukawa, T. (2021). Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. Cancers, 14.

5. Mutations in key driver genes of pancreatic cancer: Molecularly targeted therapies and other clinical implications;Hu;Acta Pharmacol. Sin.,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC);Cancer Pathogenesis and Therapy;2024-07

2. Introduction to Neoplasia;Reference Module in Biomedical Sciences;2024